Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Lenalidomide in Higher Risk MDS
NCT01053806Phase 2Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Aug 2011
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine and lenalidomide in myelodysplastic syndrome (MDS), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoint: Overall Response Rate at 2 years. Status: unknown.
02
Drugs
azacitidinelenalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01053806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01053806.